Drug Profile
Onzigolide - Tiburio Therapeutics
Alternative Names: BIM-23A760; Dopastatin; TBR-760Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Ipsen
- Developer Ipsen; Tiburio Therapeutics
- Class Antineoplastics
- Mechanism of Action Dopamine receptor agonists; Somatostatin receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Pituitary cancer
- Discontinued Acromegaly; Malignant carcinoid syndrome
Most Recent Events
- 28 Apr 2022 No recent reports of development identified for phase-I development in Pituitary-cancer in USA (SC, Injection)
- 08 Jul 2020 Phase-II clinical trials in Pituitary cancer (non-functioning pituitary adenoma) in Hungary (SC) (EudraCT2019-003142-32)
- 11 May 2020 Pharmacodynamics data from preclinical trials in Pituitary cancer (Non-functioning pituitary adenomas) released by Tiburio Therapeutics